Immuron anounces new DoD award and clinical trial updates

Immuron (IMRN) announced a new research agreement with the Naval Medical Research Command – NMRC – and the Walter Reed Army Institute of Research, or WRAIR, Silver Spring, MD, USA funded by a U.S. Department of Defense subaward.The Naval Medical Research Command and the Walter Reed Army Institute of Research, in collaboration with Immuron, are progressing the development of novel vaccines targeting Campylobacter jejuni and Shigella sonnei. Under a recently executed collaborative research agreement with the Henry M. Jackson Foundation, new vaccine preparations against these pathogens have been developed and formulated at the military research institutes and subsequently provided to Immuron. Immuron will produce two hyper-immune bovine colostrum products for pre-clinical evaluation, with the objective of advancing a combined colostrum-based therapeutic specifically designed for the US military. Also, the Uniformed Services University topline results from its clinical trial evaluating the effectiveness of enterotoxigenic E. coli hyperimmune bovine colostrum in maintaining gut health during deployment and travel are anticipated to be announced at the end of next week. In P2TD study, IMM-124E – the active ingredient in Travelan – was delivered in 600 mg powder sachets and administered twice daily in a randomized, placebo-controlled trial. Infectious diarrhea is the most common illness reported by travelers visiting developing countries and among US troops deployed overseas. In the last decade, several enteric pathogens have an increasing resistance to commonly prescribed antibiotics.